Table 3.
Use of Smoking Cessation Medication at 3 Months by Treatment Arm
| Full sample | WEB | WEB + SN | WEB + NRT | WEB + SN + NRT | |||||
|---|---|---|---|---|---|---|---|---|---|
| N = 3297 | N = 781 | N = 745 | Pairwise contrast p values | N = 902 | Pairwise contrast p values | N = 869 | Pairwise contrast p values | Omnibus p value | |
| Any cessation medication use, n (%)1 | 1942 (58.9) | 225 (28.8) | 228 (30.6) | B | 764 (84.7) | A | 725 (83.4) | A | <.001 |
| Use of study-provided NRT | |||||||||
| Any study NRT use, n (%)2 | 1450 (82.1) | — | — | — | 747 (82.8) | 707 (81.4) | .453 | ||
| Duration study NRT use (days), M (SD)3 | 14.5 (10.3) | — | — | — | 14.1 (10.1) | 14.6 (10.4) | .118 | ||
| Use of non-study medication | |||||||||
| Any non-study medication use, n (%) | 876 (26.6) | 224 (28.7) | 228 (30.6) | b | 219 (24.3) | 205 (23.6) | .002 | ||
| Any non-study NRT use, n (%)4 | 743 (84.8) | 185 (82.6) | 201 (88.2) | 184 (84.0) | 173 (84.4) | .395 | |||
| Used Zyban, n (%)4 | 64 (7.5) | 18 (8.5) | 11 (5.2) | 21 (9.6) | 14 (6.8) | .325 | |||
| Used Chantix, n (%)4 | 105 (12.4) | 38 (17.9) | 24 (11.3) | 19 (8.7) | 24 (11.7) | .028 | |||
The table only includes data from participants who completed the 3-month follow-up assessment.
1Includes study and non-study, prescription medication and NRT. 2Among WEB+NRT and WEB+SN+NRT participants who received study NRT; excludes 1 participant in the WEB arm that was inadvertently sent study NRT. 3Among those who reported study NRT use. 4Among those who reported non-study medication use.
a: Significantly different from WEB at alpha = 0.01. A: Significantly different from WEB at alpha = 0.001. b: Significantly different from WEB +SN+NRT at alpha = 0.01. B: Significantly different from WEB +SN+NRT at alpha = 0.001.